Topics: Antipsychotics | Aripiprazole | Cariprazine | Clozapine | Negative Symptoms | olanzapine | Psychopharmacology | Psychopharmacology Tips | Psychosis | Risperidone | Schizophrenia

Atypical antipsychotics are more alike than different, but a few stand out for tolerability, while others may have an edge for negative symptoms or for overall efficacy.

Topics: Antidepressant Augmentation | Antidepressants | Antipsychotics | Bipolar Disorder | Bupropion | Depression | Depressive Disorder | Escitalopram | Lamictal | Lamotrigine | Lithium | Mood Stabilizers | olanzapine | Psychopharmacology | Psychopharmacology Tips | Wellbutrin

Dr. Osser set out to develop a psychopharmacology algorithm that actually changes practice. He speaks to us on antidepressants in bipolar, psychoses that don’t need antipsychotics, and his top picks for bipolar mania, bipolar depression, and unipolar depression.

Topics: Dopamine | Geriatric Psychiatry | Neurology | Novel Medications | Nuplazid | Parkinson’s

Pimavanserin (Nuplazid) aims to treat psychosis without blocking dopamine. Though FDA-approved for psychosis associated with Parkinson’s disease, the drug is being tested in a host of other disorders: Depression, dementia, and sexual dysfunction.

Topics: Dopamine | Geriatric Psychiatry | Neurology | Novel Medications | Nuplazid | Parkinson’s

Antipsychotics remain a mainstay of delirium treatment despite significant concerns about their safety and efficacy. A pair of reports recently evaluated the evidence on their use in delirium.

After a rise of adverse psychiatric reports on montelukast (Singulair), an oral leukotriene inhibitor used for asthma and allergies, the FDA added a black box warning in March 2020 about mood and behavior changes including suicide.

Topics: CME Post-Test

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.